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Role of Sp1 in Transcription of Human ATP2A2 Gene
in Keratinocytes
Atsushi Takagi1,2, Chiharu Nishiyama1, Keiko Maeda1, Tomoko Tokura1, Hiroshi Kawada1,2,
Shunsuke Kanada1,3, Yusuke Niwa1,2, Nobuhiro Nakano1, Nobuyasu Mayuzumi2, Makoto Nishiyama4,
Shigaku Ikeda2, Ko Okumura1,3 and Hideoki Ogawa1
The ATP2A2 gene encodes Ca2þ -dependent ATPase, the dysfunction of which causes Darier disease. In this
study, we analyzed the promoter structure of the human ATP2A2 gene using primary normal human
keratinocytes (NHK). Reporter assays showed that deletion of 550/529, 488/472, 390/362, or 42/21
resulted in a significant decrease in human ATP2A2 promoter activity. Electrophoretic mobility shift assay
(EMSA) showed that Sp1 is a transcription factor that binds to the 550/529 and 488/472 regions of the
promoter. Chromatin immunoprecipitation (ChIP) assay demonstrated that Sp1, but not Sp3, binds to the
promoter region of the ATP2A2 gene in NHK cells in vivo. Knockdown of Sp1 expression by small interfering
RNA resulted in a marked reduction in ATP2A2 promoter activity and ATP2A2 mRNA levels in NHK, suggesting
that Sp1 positively transactivates the ATP2A2 promoter in NHK. This is early evidence demonstrating that Sp1
plays an important and positive role in ATP2A2 gene expression in NHK in vivo and in vitro.
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INTRODUCTION
Darier disease (DD) is an autosomal-dominant skin disorder
characterized by warty papules and plaques in the seborrheic
area, palmo-plantar pits, and distinctive nail abnormalities.
The typical histological features are loss of adhesion between
epidermal cells (acantholysis) and abnormal keratinization
(dyskeratosis), occasionally accompanied by a wide range of
neuropsychiatric problems, including epilepsy and depres-
sion. In 1999, the human ATP2A2 gene encoding the
sarcoplasmic/endoplasmic reticulum Ca2þ -ATPase 2 (SER-
CA2) was identified as the defective gene in DD, because
several mutations were found in this gene in DD patients
(Sakuntabhai et al., 1999b). According to several studies
regarding SERCA2 proteins carrying the mutations found in
the ATP2A2 gene in DD patients, it is believed that DD is
caused in most cases by SERCA2 haploinsufficiency (Ahn
et al., 2003; Dhitavat et al., 2003; Dode et al., 2003; Sato
et al., 2004; Foggia et al., 2006). These observations indicate
that elucidating the mechanism of the ATP2A2 gene
expression would provide insight into restoring the decreased
function of SERCA2 in DD keratinocytes.
To date, there have been no reports on the mechanisms for
transcriptional regulation of the human ATP2A2 gene in
keratinocytes, although the gene product, SERCA2, is
important for normal Ca2þ homeostasis of keratinocytes,
and decreased expression and/or activity results in occur-
rence of DD. In this study, we analyzed the regulatory
mechanisms of human ATP2A2 gene transcription in primary
normal human keratinocytes (NHK) using luciferase reporter
assay and electrophoretic mobility shift assay (EMSA), and
identified a transcription factor Sp1, as a nuclear protein
binding to critical cis-elements of the ATP2A2 promoter in
vitro. Furthermore, we confirmed that Sp1 actually binds to
the promoter region on chromatin in living keratinocyte cells
by chromatin immunoprecipitation (ChIP) assay and that
downregulation of Sp1 expression by small interfering RNA
(siRNA) resulted in suppression of ATP2A2 promoter activity
and transcription levels.
RESULTS
Determination of transcriptional regulatory region of the
human ATP2A2 promoter
In order to determine the regulatory region required for
expression of the human ATP2A2 gene, a series of reporter
plasmids carrying various length of the 50-flanking region of
the human ATP2A2 gene were constructed. Each of these
reporter plasmids was introduced into NHK and luciferase
activity derived from NHK cells transfected with each
plasmid was measured. The 679/þ 61 region showed
significant promoter activity (approximately 95-fold) when
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compared with the basic control (Table 1). Deletions of
622/529, 528/419, and 418/307 caused significant
decreases in promoter activity. Furthermore, the shortest
region, 90/þ61, still possessed apparent promoter activity.
These results suggest that the 622/529, 528/419,
418/307, and 90/þ61 regions contain cis-enhancing
elements.
We generated additional reporter plasmids in an attempt
to further identify the cis-enhancing elements located in
above-mentioned regions. The deletions between 679 and
528 is shown in Table 2a. A deletion of 22 bp from 550 to
528 resulted in a marked reduction of promoter activity,
thus, suggesting that one of cis-enhancing elements is present
in 550/529. Similarly, deletions from 488 to 472
(Table 2b), from 390 to 362 (Table 2c), and from 42 to
21 (Table 2d) caused significant decreases in promoter
activity. These results indicate that cis-enhancing elements of
the human ATP2A2 promoter are present in four regions;
550/529, 488/472, 390/362, and 42/21.
Identification of transcription factor binding to cis-enhancing
elements of human ATP2A2 gene
In order to identify the transcription factor(s) binding to cis-
enhancing elements in the human ATP2A2 promoter, we
performed EMSA using nuclear extracts prepared from
keratinocyte cells. When EMSA was performed with probe
oligonucleotides for 391/359 or 41/19, no specific
bands, which disappeared in the presence of wild-type
competitors and did not disappear in the presence of mutant
competitors, were observed (data not shown). In contrast, we
identified a specific band in each EMSA using probe
oligonucleotides for 550/524 or 488/465 (arrows
in Figure 1a and 1b, respectively). We identified several
possible recognition motifs for transcription factors, includ-
ing Sp1 and AP-2, in these two regions using the motif
analysis program TFSEARCH (http://www.cbrc.jp/research/
db/TFSEARCH.html) (Figure 4). This band completely dis-
appeared by adding anti-Sp1 antibody (Ab) to the EMSA
reaction mixture (lane 2 in Figure 1a), but remained even in
the presence of anti-Sp3 and anti-AP-2a Abs (lanes 3 and 4 in
Figure 1a). Similarly, anti-AP-2b and anti-AP-2g Abs did not
affect this band shift (data not shown). A specific band with
the 488/465 probe also disappeared by addition of anti-
Sp1 Ab but was still observed in the presence of anti-Sp3,
-AP-2a, -AP-2b, and -AP-2g Abs (lanes 2–6 in Figure 1b).
These results demonstrate that Sp1 binds to the human
ATP2A2 promoter via Sp1-binding motifs in 550/524
and 488/465 in vitro.
Table 1. Determination of the transcriptional
regulatory region of the human ATP2A2 promoter by
luciferase assay
Relative luciferase activity
Promoter region Average7SE
679/+61 95.772.7
622/+61 80.9716.3
528/+61 52.879.6
418/+61 23.674.3
306/+61 14.875.6
192/+61 9.873.6
90/+61 8.871.6
Relative promoter activity is represented as the ratio against that of pGL3-
Basic (promoter less plasmid), and the results are expressed as mean7SE
of more than quadrant samples in Tables 1 and 2. Representative results of
five independent experiments are shown. Po0.05, between 622/+61
and 528/+61; Po0.005, between 418/+61 and 306/+61, and
between 90/+61 and promoter less; Po0.0005, between 528/+61
and 418/+61.
Table 2. Mapping of cis-enhancing elements in
50-flanking region of human ATP2A2 gene
Relative luciferase activity
Promoter region Average7SE
(a)
Fine mapping of cis-enhancing elements in 679/528
679/+61 20.073.6
622/+61 27.779.0
550/+61 24.974.6
528/+61 10.773.4
(b)
Fine mapping of cis-enhancing elements in -528/-418
528/+61 120.578.7
508/+61 130.5722.6
488/+61 101.6721.0
471/+61 47.877.0
445/+61 58.477.7
418/+61 39.276.6
(c)
Fine mapping of cis-enhancing elements in 418/306
411/+61 21.472.9
390/+61 36.4712.5
361/+61 7.773.6
332/+61 7.171.8
306/+61 10.277.3
(d)
Fine mapping of cis-enhancing elements in 90/20
90/+61 4.971.0
42/+61 5.171.6
20/+61 0.04270.027
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In vivo binding of Sp1 to promoter region of human ATP2A2
gene
ChIP assay was performed in an effort to examine whether
Sp1 protein binds to human ATP2A2 promoter region in
keratinocytes in vivo. A markedly higher amount of
chromatin containing the ATP2A2 promoter region was
immunoprecipitated by anti-Sp1 Ab when compared with
control IgG (Figure 2a). In contrast, the amount of chromatin
immunoprecipitated by anti-Sp3 Ab was comparable with
that by control IgG (Figure 2a). Both anti-Sp1 and anti-Sp3
Abs did not immunoprecipitate cis control region of ATP2A2
gene specifically (Figure 2b). These results suggest that Sp1
but not Sp3, a similar transcription factor belonging to same
family, binds to the ATP2A2 promoter region of chromatin in
human keratinocytes.
Knockdown of Sp1 expression by siRNA downregulates
promoter activity and transcription of ATP2A2
ChIP assay revealed that a significant amount of Sp1
occupied human ATP2A2 promoter in keratinocytes. To
evaluate the effects of Sp1 on ATP2A2 expression, Sp1 siRNA
or control was introduced into keratinocytes, and the Sp1
mRNA in each transfectant was determined using quantita-
tive real-time PCR. Sp1 siRNA reduced Sp1 mRNA level by
85% under the condition of approximately 60–90% of
transfection efficiency (Figure 3a), whereas control siRNA
had no effect on Sp1 mRNA levels (Figure 3b). Reduced Sp1
protein level was also observed by Western blot analysis
(Figure 3c). Co-transfection of keratinocytes with Sp1 siRNA
and reporter plasmid confirmed that the luciferase activity
driven by the ATP2A2 promoter was significantly lower in
Sp1-siRNA transfectant than that in control-siRNA transfec-
tants (Figure 3d). In contrast, the presence of Sp1 siRNA did
not affect the luciferase activity derived from control
transfectant carrying pGL3-Basic (Figure 3d). When ATP2A2
mRNA levels were measured by real-time PCR, significant
suppression of ATP2A2 transcription (approximately 60%)
was observed in Sp1-siRNA transfectants (Figure 3e). These
results indicate that Sp1 positively regulates the expression of
human ATP2A2 in keratinocytes by transactivating the
promoter.
Probe
Antibody Sp1 Sp1Sp3 Sp3AP-2
AP-2
Probe–550/–524 –488/–465
(–) Antibody (–)   
Figure 1. Identification of transcription factor binding to cis-enhancing elements in human ATP2A2 promoter by EMSA. EMSA was performed with
FITC-labeled probe corresponding to (a) 550/528 or (b) –488/-465 with nuclear extract from NHK.
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Figure 2. Sp1 binds to human ATP2A2 promoter region in vivo. Binding
between the human ATP2A2 promoter (a) or cis control region of ATP2A2
gene (b) and Sp1 or Sp3 was analyzed by ChIP assay using anti-Sp1, anti-Sp3,
or isotype control Ab (mouse IgG1 and mouse IgG2a as controls for anti-Sp1
and anti-Sp3, respectively). Binding was quantitatively analyzed by real-time
PCR. Relative input units are calculated from cycle threshold values as
described in ‘‘Materials and Methods’’. Results are expressed as means7SD
of triplicate samples. Representative results of three independent
experiments are shown.
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DISCUSSION
ATP2A2 encodes the SERCA2, which belongs to a family of
P-type membrane-bound ATPases and transports Ca2þ from
the cytoplasm into reservoirs in the endoplasmic reticulum.
As the early evidence showing mutations in human ATP2A2
gene to be the cause of DD (Sakuntabhai et al., 1999b),
various mutations, including missense mutations, nonsense
mutations, and mutations causing frame-shifts and abnormal
splicing, have been identified in the ATP2A2 gene in DD
patients (Jacobsen et al., 1999; Ruiz-Perez et al., 1999;
Sakuntabhai et al., 1999a; Ringpfeil et al., 2001; Takahashi
et al., 2001; Yang et al., 2001). Several studies on SERCA2
mutations found in DD patients suggest that reduced
expression of SERCA2 owing to haploinsufficiency is the
main cause of DD (Ahn et al., 2003; Dhitavat et al., 2003;
Dode et al., 2003; Sato et al., 2004; Foggia et al., 2006).
These observations prompted us to analyze the expression
mechanism of the human ATP2A2 gene in keratinocytes, as
we believe that elucidation of this mechanism will be useful
for further understanding the cause of DD and for developing
new therapeutic methods for DD.
In this study, we used reporter assay and EMSA to identify
a transcription factor Sp1, which binds to critical cis-
enhancing elements on the human ATP2A2 promoter.
Furthermore, we confirmed the in vivo binding of Sp1 to
the ATP2A2 promoter region on chromatin in keratinocytes
by ChIP assay and the involvement of Sp1 in ATP2A2
transcription in keratinocytes using siRNA. Although Sp1 is a
widely expressed transcription factor, Sp1 has been con-
firmed to be involved in the transcriptional regulation of
keratinocyte-specific genes, including transglutaminase 3
(Lee et al., 1996), loricrin (Jang and Steinert, 2002),
involucrin (Eckert et al., 2004; Crish et al., 2006), keratin 5
(Kaufman et al., 2002), peptidylarginine deiminase type III
(Dong et al., 2006), DNp63 (Romano et al., 2006), and
profilaggrin (Markova et al., 2006). We have also found that
Sp1 is involved in the promoter activity of the Hailey–Hailey
disease (HHD)-related gene human ATP2C1 in keratinocytes
(Kawada et al., 2005). In that study, the amount of nuclear
Sp1 was elevated by stimulation of normal keratinocytes with
increased concentrations of Ca2þ in culture medium
(Kawada et al., 2005). On the other hand, it is reported that
extracellular Ca2þ induces growth suppression and differ-
entiation of NHK (Hennings et al., 1980). Furthermore,
upregulation of Sp1 activity induces the expression of the
differentiation-specific molecule transglutaminase type 1
in keratinocytes (Wong et al., 2005). These observations
suggest that Sp1 plays an important role in keratinocyte-
specific gene expression induced or enforced by differentia-
tion of keratinocytes.
As described above, several genes are under the control of
Sp1 in keratinocytes. Therefore, in the knockdown experi-
ment in this study, we cannot completely exclude the
possibility that reduction of ATP2A2 expression may be due
to the indirect effect of reduced expression of Sp1, which
suppresses the expression of various target genes. Although
further detailed analysis will be required to clarify this issue,
we believe that ATP2A2 expression is downstream of Sp1 and
that direct regulation by Sp1 indicated by reporter assay,
EMSA, and ChIP assay is one of the mechanism of ATP2A2
gene regulation.
When nucleotide sequence of human ATP2A2 promoter is
analyzed by UCSC (http://genome.ucsc.edu/cgi-bin/hgTracks),
three regions (Figure 4) are identified as highly conserved
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Figure 3. Knockdown of Sp1 expression by siRNA results in downregulation of ATP2A2 promoter activity. (a) Fluorescence microscopy of FITC-labeled control
oligonucleotide-introduced keratinocytes. After 24 hours culture from transfection of oligonucleotides, cells were washed and visualized by phase microscopy to
visualize cells (left) and by fluorescence microscopy using a green fluorescent protein filter (right). Bar¼ 100mm. (b) Sp1 mRNA level in Sp1 siRNA-treated
keratinocytes analyzed by real-time PCR. (c) Sp1 protein level in Sp1 siRNA-treated keratinocytes analyzed by Western blotting. (d) Transcription activity
of human. ATP2A2 promoter in Sp1 siRNA-introduced keratinocytes. The ratio of luciferase activity in each transfectant to that in cells transfected with
pGL3-Basic and control siRNA is given as relative activity. (e) ATP2A2 mRNA level in Sp1 siRNA-introduced keratinocytes analyzed by real-time PCR.
www.jidonline.org 99
A Takagi et al.
Regulation of Human ATP2A2 Promoter by Sp1
sequences. Interestingly, two of three regions at 50-site
contain Sp1-binding sites identified in this study, suggest-
ing a possibility that Sp1 regulates ATP2A2 gene expres-
sion not only in human but also in other species. The last
one at just upstream of transcription start site may be
important for basal transcriptional machinery including
RNA polymerase.
ATP2A2 was also expressed in other tissues, including the
brain, and DD has been reported to be associated with
certain neuropsychiatric illness. Considering that Sp1 is a
ubiquitous transcription factor and regulates transcription of
several genes in brain (Gui et al., 2006; Ramos et al., 2007),
Sp1 may control ATP2A2 expression in brain as well as
keratinocytes. Alternatively, other transcription factors in-
cluding other Sp1-factors may regulate ATP2A2 transcription
in brain, as the case of NFkB element in superoxide
dismutase-2 gene, which was dominantly occupied by Sp3
and Sp4 in neurons, whereas Sp1, Sp3, and NFkB bound this
site in astroglia (Mao et al., 2006). Regardless, further study is
required to reveal the involvement of Sp1 in ATP2A2 gene
expression in other tissues.
In keratinocytes from HHD patients, Sp1 protein levels in
the nucleus are not increased by higher concentrations of
extracellular Ca2þ because of incomplete Ca2þ response
due to malfunction of ATP2C1 (Kawada et al., 2005).
Abnormalities in Ca2þ -pumps such as ATP2C1 and ATP2A2
may result in incomplete expression of Sp1-mediated
genes (including ATP2C1 and ATP2A2 themselves) in
the Ca2þ -induced differentiation stage of keratinocytes.
It is possible that the defects in cell-to-cell adhesion
observed in DD and HHD are typically present in the
suprabasal layers of the epidermis where keratinocytes are in
the final stage of differentiation. Therefore, restoration of
Sp1 activity to normal level in a Ca2þ -signaling indepen-
dent manner may be a useful approach for treatment of
DD and HHD.
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Figure 4. Nucleotide sequence of the 50-flanking region of the human ATP2A2 gene. The transcription initiation site is indicated as þ 1, based on the 50-end
of the human ATP2A2 mRNA sequence (accession number NM_170665). Possible transcription factor binding sites found in cis-enhancing elements identified
by the publicly available MOTIF search services are underlined, and Sp1-binding sites confirmed by EMSA are boxed. This genomic region corresponds to
109203135/109203873 of chromosome 12 published in NCBI human genomic DNA sequence site. Three regions underlined with dotted black line are
identified to be highly conserved sequences by UCSC (chromosome 12: 109203326–109203493, lod¼178; chromosome 12: 109203225–109203285,
lod¼ 41; chromosome 12: 109203813–109203827, lod¼28).
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To date, factors including transforming growth factor-b
(Sakaguchi et al., 2005), PGE2 (Kanda et al., 2005;
Matlhagela et al., 2005), 12-O-tetradecanoylphorbol 13-
acetate, (Matlhagela et al., 2005), and 17b-estradiol (Kanda
and Watanabe, 2005) have been reported to induce activa-
tion of Sp1, thus suggesting that the mechanism of Sp1
activation via these factors is important for normalization of
reduced Sp1-mediated gene expression levels in DD- and
HHD-keratinocytes. Previously, S100C/A11-mediated post-
translational regulation of Sp1 was reported in the analysis of
Ca2þ -induced growth inhibition of keratinocytes (Sakaguchi
et al., 2003), where an increase in intracellular
Ca2þ activates protein kinase C, which leads to phos-
phorylation of S100C, resulting in release of free Sp1
from nucleolin, which provides a site for switching trans-
criptional activation of Sp1 through protein–protein
interaction. Therefore, we are further analyzing the effects
of other factors, such as transforming growth factor-b on
activation of Sp1 in order to rescue the reduced expression
of ATP2A2 and ATP2C1, as well as other genes observed
in differentiated keratinocytes, as a possible therapeutic
approach for DD and HHD.
MATERIALS AND METHODS
Cell culture
NHK derived from normal newborn foreskin were purchased from
KURABO (Osaka, Japan) and cultured in a serum-free standard
medium Epilife-KGM (KURABO) containing 0.06 mM Ca2þ , 10mg/
ml insulin, 0.1 ng/ml hEGF, 0.5 mg/ml hydrocortisone, 50 mg/ml
gentamicin, 50 ng/ml amphotericin-B, and 0.4% bovine pituitary
extract. Second-to-fourth-passage keratinocytes in monolayer at
60–90% confluence were used. All experiments were performed
according to the approved manual of the institutional review board
of Juntendo University School of Medicine, Japan, adhered to the
Declaration of Helsinki Principles.
Plasmid construction
The 50-flanking region of approximately 740 bp including a 50-
untranslated (UT) region of the human ATP2A2 gene was amplified
by PCR from human genomic DNA, which was purified from
peripheral blood using a DNA quick kit (Dainippon Pharmaceutical,
Osaka, Japan). The following synthesized oligonucleotides were
used as primers: 50-agatctCCCACCCTGCGTCTGCAGGTGGGTGG
GTCAGAG-30, and 50-aagcttACGGGCTCTCCCCTCCTCCTCTTGCG
GCCGCTT-30 (replaced nucleotides for introduction of BglII and
HindIII sites are shown in lowercase letters). This genomic region
corresponds to 109203135/109203873 of chromosome 12 pub-
lished in (NCBI) National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/). The amplified DNA fragment was
inserted into the BglII/HindIII site of pGL3-Basic (Promega, Madison,
WI). Other reporter plasmids carrying various length of the ATP2A2
promoter were constructed by PCR in a similar manner or via a
newly introduced BglII site at the appropriate positions in the
promoter using a QuikChange site-directed mutagenesis kit (Strata-
gene, La Jolla, CA). The nucleotide sequences of the human ATP2A2
promoter in all reporter plasmids were confirmed by sequencing
analysis using an ABI PRISM377 DNA sequencer (Applied Biosys-
tems, Foster City, CA).
Luciferase assay
NHK cells (1 105) cultured in six-well plates were transfected with
2mg reporter plasmid, and 250 ng pRL-null (Promega), which was an
internal control for transfection efficiency, by Fugene6 (Roche
Diagnostics, Indianapolis, IN). After 20–24 hours of culture, cells
were harvested and the luciferase activity of each cell lysate was
measured using a Dual-luciferase assay kit (Promega) and a
luminescence detector, Micro Lumat Plus (Berthold, Postfach,
Germany) as described previously (Akizawa et al., 2003).
EMSA
Probes were prepared by annealing two synthesized 50-FITC-labeled
oligonucleotides (Invitrogen, Carlsbad, CA) having complementary
sequences. The sequences of the sense strand of probes were as
follows: 50-GGGAGGGGGCGGGGCCTGCGCGGCAGC-30 for –550/
524, 50-GGAGGGGGCGGGGCCGCGCCGCCC-30 for –488/465,
50-CCGATAAATGCTATTAGAGCAGCCGCCGCGGA-30 for –391/
359, and 50-TCGGGGCCGCGCGAGGGGCGGTT-30 for –41/19.
Nuclear proteins were extracted from NHK as described previously
(Nishiyama et al., 1999; Maeda et al., 2003). Each probe (5 pmol)
was mixed with nuclear extract containing 5 mg of protein in the
buffer (Nishiyama et al., 1999) and was applied to a 4%
polyacrylamide gel. To identify the transcription factors binding to
the probe, 1mg of Ab against Sp1 (clone no. 1C6, cat no. sc-420X,
mouse IgG1), Sp3 (clone no. F-7, cat no. sc-28305X, mouse IgG2a),
AP-2a (clone no. 3B5, cat no. sc-12726X, mouse IgG2b), AP-2b
(clone no. H-87, cat no. sc-8976X, rabbit IgG) or AP-2g (clone no.
6E4/4, cat no. sc-12762X, mouse IgG1) was added to the mixture.
After electrophoresis for 2 hours at 250 V, gels were placed in a
fluorescence detector, FluoroImager 595 (Molecular Dynamics,
Sunnyvale, CA).
Quantitative ChIP assay
ChIP assay was performed as described previously using a ChIP
Assay Kit (Upstate, Lake Placid, NY) with a modification for use of
protein G (Upstate) instead of protein A (Maeda et al., 2006). Anti-
Sp1 Ab, anti-Sp3 Ab, and mouse IgG1 (no. 553485) and IgG2a (no.
553454) (BD Pharmingen, San Diego, CA) were used as controls in
ChIP assay. The amounts of Sp1 and Sp3 bound to the promoter
region of the human ATP2A2 gene were quantified using a 7500
Real-Time PCR System (Applied Biosystems, Foster City, CA). Briefly,
fluorescence was evaluated in each well of 96-well plates (Applied
Biosystems) containing TaqMan Universal PCR Master Mix (Applied
Biosystems), and immunoprecipitate was monitored and cycle
threshold values in amplification plots were calculated using 7500
SDS software (Applied Biosystems). The ratio of specific DNA
fragments in each immunoprecipitate against input DNA was
calculated from cycle threshold values. Nucleotide sequences of
primers and a TaqMan probe are as follows: to detect the –580/364
region of the human ATP2A2 gene, forward primer (50-
CCTCGATCCGGGTTCCTAG-30 for 580/562), reverse primer
(50-GGCGGCTGCTCTAATAGCAT-30 for 364/384), and TaqMan
probe (50-FAM-CTGGCGCCCACGC-MGB-30 for -513/-525). For
the cis control region (þ 54456/þ 54536), forward primer (50-TGGA
GCTTGGATTCCTATGGA-30 for þ 54456/þ 54476), reverse primer
(50-CATGGTGATGACAGACAGGTAGGT-30 for þ 54536/þ 54513),
and TaqMan probe (50-FAM-TCTGCTGAACATACCTC-MGB-30 for
þ 54484/þ 54500).
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Knockdown of Sp1 expression by siRNA
In order to suppress the expression of Sp1 in keratinocytes, siRNA
was used. Ten microliters of 20 mM Sp1 siRNA, non-silencing control,
or FITC-labeled control oligonucleotide (Validated Stealth RNAi
DuoPak no. 12936-62; Invitrogen) was introduced into 1 105 of
keratinocytes with lipofectamine (Invitrogen) according to the
manufacturer’s instructions. Transfection efficiency of keratinocytes
treated with FITC-labeled control oligonucleotides was analyzed by
using a fluorescence microscopy BZ-8000 (Keyence Co., Woodcliff
Lake, NJ).
Quantification of Sp1 and ATP2A2 mRNA by real-time PCR
The amounts of Sp1 and ATP2A2 mRNA were quantified using a
7500 Real-Time PCR System with Assays-on-Demand gene expres-
sion products (Applied Biosystems) of human Sp1 (Hs00412720),
human ATP2A2 (Hs00155939), and endogenous controls (Human
glyceraldehyde-3-phosphate dehydrogenase; no. 4326317E).
Expression levels of Sp1 and ATP2A2 are given relative to those
of glyceraldehyde-3-phosphate dehydrogenase based on cycle
threshold values as described previously (Nishiyama et al., 2004).
Western blot analysis
Cell lysates (1 106 cells) from each transfectant were subjected to
electrophoresis on a 7.5%. SDS polyacrylamide gel. The anti-Sp1 Ab
(clone no. 1C6) or anti-actin Ab (clone no. C-2, cat no. sc-8432,
mouse IgG1; Santa Cruz Biotechnology, Santa Cruz, CA) was used as
the primary Ab. Alexa Fluor 680 goat anti-mouse IgG (no. A-21058,
Molecular Probes Inc., Eugene, OR) was used as the secondary Ab.
Infrared fluorescence on membranes was detected by Odyssey
infrared imaging system (Model ODY-9201-SC, LI-COR Inc.,
Lincoln, NE).
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